| 5 star (3) | 100% |
Art (California) on 05/06/2026: 
This new review article suggests that melatonin is useful for two types of AMD, wet AMD and dry AMD.
Here is a link to the full review :
https://pmc.ncbi.nlm.nih.gov/articles/PMC13116036/
Here is a relevant quote from the review of studies :
' A major objective of this review is to examine the role of melatonin, a powerful and multifunctional antioxidant, in altering the trajectory of AMD progression. Melatonin is synthesized in the RPE and photoreceptors of young individuals but its expression declines with age. As shown in an epidemiological report, its loss contributes to age-related degeneration of the RPE and photoreceptors. Moreover, melatonin inhibits VEGF, suggesting that it would be useful as a treatment for wet AMD. This review explores melatonin-mediated protective mechanisms in the retina, a likely mechanistic basis for the already published findings showing that melatonin use by humans is associated with delayed AMD, and potential clinical applications. '
Art
Art (California) on 06/27/2025:
This newer study suggests that melatonin significantly decreases the risk of getting AMD while in existing cases melatonin had a negative impact on disease progression as discussed here :
Here are two relevant quotes from the large cohort study :
; Melatonin use was associated with a decreased risk of development and progression of AMD. '
; Among patients aged 50 years or older, those in the melatonin cohort had a reduced risk of receiving an AMD diagnosis compared with the control cohort (RR, 0.42; 95% CI, 0.28-0.62). The analysis of the older subsets of patients revealed similar findings (aged ≥60 years: RR, 0.36 [95% CI, 0.25-0.54]; aged ≥70 years old: RR, 0.35 [95% CI, 0.23-0.53]). Such associations persisted even when patients were monitored for AMD development at least 2 years after the index event (aged ≥50 years: RR, 0.22 [95% CI, 0.12-0.39]; aged ≥60 years: RR, 0.40 [95% CI, 0.19-0.83]; aged ≥70 years: RR, 0.22 [95% CI, 0.12-0.43]). Likewise, our sensitivity analyses revealed consistent results with that of the primary analysis (eTables 6-8 in Supplement 1). The negative control outcome analysis showed that melatonin treatment was not associated with the risk of head injuries (eTable 9 in Supplement 1). '
The list of health benefits associated with melatonin use continues to grow significantly!
Art
cjuan (Malaysia) on 06/09/2021:
